Aridis Pharmaceuticals - Articles and news items

Aridis’ human monoclonal antibody pneumonia trial a safe success

Industry news / 9 January 2017 / Niamh Marriott, Digital Editor

AR-301 (Salvecin) is a fully human monoclonal IgG1 antibody that specifically targets S. aureus alpha-toxin and protects host cells from destruction…

Aridis expands Phase 2a trial of AR-301 into the US

Industry news / 9 July 2015 / Victoria White

The US Food and Drug Administration (FDA) has accepted Aridis Pharmaceuticals’ Investigational New Drug (IND) application for AR-301 (Salvecin)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+